Physician profile
Mark Boyack
NPI 1750323986
$3,878.70
in general payments reported to CMS, 2019-2025
24 companies · $887 in 2025
The $887 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $272 · 2022: $448 · 2023: $1,116 · 2024: $1,155 · 2025: $887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,551 · Honoraria: $594 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,551.21 |
| Honoraria | $594.00 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $690.03 | 2022-2025 | |
| Horizon Therapeutics Plc | $609.98 | 2022-2023 | Procysbi |
| Amgen INC. | $537.95 | 2021-2025 | Tavneos, Krystexxa, Otezla |
| Otsuka America Pharmaceutical, INC. | $496.93 | 2021-2025 | Jynarque, Rexulti |
| Astrazeneca Pharmaceuticals LP | $486.39 | 2021-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $212.55 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $154.43 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $108.51 | 2021-2025 | Benlysta |
| Ani Pharmaceuticals, INC. | $107.50 | 2023-2025 | Purified Cortrophin Gel |
| Baxter Healthcare | $105.63 | 2024-2025 | Renal - Pd, Hillrom - Vest System Model 105 Home Care |
| Alexion Pharmaceuticals, INC. | $67.46 | 2022-2025 | Ultomiris |
| Lilly USA, LLC | $50.70 | 2023-2024 | Jardiance |
| Novo Nordisk INC | $33.73 | 2022 | |
| Ardelyx, INC. | $32.43 | 2024-2025 | Ibsrela |
| Hologic Sales and Service, LLC | $29.37 | 2024 | Myosure Tissue Removal Device |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $26.65 | 2025 | Remodulin, Orenitram |
| Mallinckrodt Hospital Products INC. | $22.58 | 2024 | Acthar |
| Aurinia Pharma U.S., INC. | $20.62 | 2021 | |
| Alnylam Pharmaceuticals INC. | $16.22 | 2022 | |
| Opko Pharmaceuticals, LLC | $14.76 | 2021 | |
| Ascendis Pharma Endocrinology INC | $14.46 | 2025 | Yorvipath |
| Vifor Pharma, INC. | $14.22 | 2025 | Veltassa |
| Merck Sharp & Dohme LLC | $13.37 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $12.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Boyack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.